Staff Catalogue


Department of Psychology
FEB 02 - Faculty of Economics and Management, B117
Dr. Zanos is currently an Assistant Professor of Neuropharmacology at the Department of Psychology, University of Cyprus. He graduated with a BSc (Hons) in Biochemistry in 2010 and he then received his Ph.D. in Neuropharmacology in 2013 from the University of Surrey, U.K. After 5 years of postdoctoral training, he was promoted to an Instructor (2018)  and then Assistant Professor at the Department of Psychiatry of the University of Maryland in the USA (2019-2021).
Dr. Zanos is the Head of the Translational Neuropharmacology Lab, which fosters a dynamic interdisciplinary research team based in the beautiful city of Nicosia, Cyprus. Our diverse team brings together a wide range of expertise, including specialists in Drug Repurposing, Molecular and Behavioral Pharmacology, Drug Discovery, Neuroscience, Clinical Psychology, Medicinal Chemistry, and Systems Bioinformatics. With our lab having three research units: Translational Neuropharmacology, Clinical Neuropsychopharmacology, and Systems Bioinformatics. Embracing innovation, we integrate experimental techniques, including in vitro, ex vivo, and in vivo rodent models, along with bioinformatics methodologies and genetic epidemiology, to unravel the complexities of different brain diseases, and other comorbid conditions. Our specific focus lies on neurodegenerative and neurodevelopmental diseases, as well as neuropsychiatric disorders. Notably, we are the first lab to ever conduct a drug-interventional clinical trial in Cyprus, marking a significant milestone in our research efforts. In this trial, we are repurposing the anesthetic drug ketamine for treating opioid use disorders.

In our quest for a healthier future, we go beyond traditional approaches. Our mission extends to exploring the potential of drug repurposing, leveraging the vast knowledge within our team to identify novel solutions for complex conditions. By combining our strengths in diverse fields, we aim to drive innovation and advance our understanding of these intricate disorders.

For more information visit: Translational Neuropharmacology Lab

Dr. Zanos is a leading figure in the field of brain diseases, dedicated to uncovering innovative therapies for major depressive disorders and related brain disease, which present a pressing global health challenge. His groundbreaking research holds the promise of transforming the treatment landscape and making a profound impact on the lives of millions suffering from depression and comorbid opioid use disorders. Dr. Zanos has emerged as a leading figure in the search for improved antidepressant therapies, particularly through his pioneering research on the use of ketamine metabolites as rapid-acting antidepressants. By discovering the efficacy of these metabolites while minimizing harmful side effects, Dr. Zanos has provided a groundbreaking solution to a critical problem in depression treatment. His groundbreaking discoveries on the metabolites of ketamine have not only advanced our understanding of how ketamine works as an antidepressant medication, but have also paved the way for a phase I clinical trial conducted in collaboration with the National Institute of Mental Health ( NCT04711005) to assess ketamine’s metabolite (2R,6R)-hydroxynorketamine in humans. The successful outcomes of this initial trial have positioned the research project for the next crucial phase (phase II clinical trial), which is expected to begin very soon, demonstrating the high translational potential and significance of Dr. Zanos’ work.

Dr. Zanos established his independent laboratory at the University of Cyprus in August 2021, and in less than 2 years, he has achieved remarkable accomplishments. Notably, he has secured over €1.250,000 in competitive grant funding from both national and international sources. Despite being an early career researcher, Dr. Zanos has already authored more than 60 peer-reviewed journal articles, including prestigious publications in renowned journals such as NatureNature NeuroscienceMolecular PsychiatryBiological PsychiatryProceedings of the National Academy of SciencesNeuronBritish Journal of Pharmacology and others. His work has gained global recognition and widespread attention, with coverage in esteemed news platforms worldwide. Furthermore, his research has been extensively cited by the scientific community, accumulating over 5900 total citations (h-index: 31). Furthermore, Dr. Zanos has forged significant partnerships with prominent figures in the addiction and depression research domain, including experts from the National Institutes of Health (NIH). These collaborations highlight the collaborative nature of his work and its potential impact. In addition to his wide network of international collaborations, Dr. Zanos actively participates in large-scale collaborative initiatives and currently serves as the Principal Investigator (PI) in a groundbreaking clinical trial. The trial investigates the efficacy of ketamine in preventing relapse to opioid use in abstinent patients (EudraCT: 2022-001997-70), marking the first-ever clinical trial conducted using drug treatment in a clinical population in Cyprus. 

Beyond his groundbreaking research on ketamine and its metabolites, Dr. Zanos has made substantial contributions in diverse domains of neuropharmacology. His studies investigating the role of oxytocin and its dysregulation in drug addiction have provided valuable insights into potential avenues for medication development. These findings have also prompted the initiation of a human clinical trial to evaluate the effectiveness of oxytocin in individuals with opioid addiction. Furthermore, Dr. Zanos’s investigations into receptor interactions, genetic vulnerabilities, and sleep disorders have significantly enhanced our understanding of complex mental health conditions, such as depression and substance use disorders.

Relevant links:


Contact info:

E-mail: [email protected]

Phone: (+357) 22892243


  • Thomas, C., Raja, S., Guptill, J., Mack, M., Peterson, M., Byard, S., Twieg, L.J., Rich, N.., Castledine, R., Bourne, S., Wilmshurst, M., Oxendine, S., Avula, S., Zuleta, H., Quigley, P., Lawson, S., McQuaker, S., Ahmadkhaniha, R., Appelbaum, L., Kowalski, K., Barksdale, C., Gufford, B., Awan, A., Sancho, A., Zanos P., Gilbert, J., Morris, P., Moaddel, R., Gould, T.D., Carlos, A.Z. A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers. Clinical Pharmacology & Therapeutics, 2024, In Press
  • Onisiforou, A., Zanos, P., Georgiou, P. Molecular signatures of premature aging in major depression and substance use disorders. Scientific Data, 2024, In Press
  • Onisiforou, A., Zanos, P., Georgiou, P. Neuroendocrine Regulation of Anxiety. In: Charis, C., Panayiotou, G. (eds) Anxiety Disorders and Related Conditions. Springer, Cham.
  • Onisiforou, A., Zanos, P. From viral infections to Alzheimer’s Disease: Unveiling the mechanistic links through Systems Bioinformatics. Journal of Infectious Diseases, 2024, In Press.
  • Onisiforou, A., Zanos, P., Georgiou, P. Molecular signatures of premature aging in major depression and substance use disorders. Scientific Data, 2024, In Press.
  •  Onisiforou, A., Zanos, P., Georgiou, P. Neuroendocrine Regulation of Anxiety. In: Charis, C., Panayiotou, G. (eds) Anxiety Disorders and Related Conditions. Springer, Cham.
  • Onisiforou, A., Zanos, P., Georgiou, P. Molecular signatures of premature aging in major depression and substance use disorders. Scientific Data, 2024, In Press.
  • Onisiforou, A., Zanos, P., Georgiou, P. Neuroendocrine Regulation of Anxiety. In: Charis, C., Panayiotou, G. (eds) Anxiety Disorders and Related Conditions. Springer, Cham.
  • Georgiou, A., Voskarides, K., Zanos, P., Chatzittofis, A. Investigating the shared genetic basis and causal relationships between mucosa-associated lymphoid tissue inflammation and psychiatric disorders. Frontiers in Psychiatry, 2024, In Press.
  • Nguyen, TML.,  Guilloux, J-P.,  Defaix, C., Mendez-David, I., Etting, I., Alvarez, J-C., McGowan, J.C., Highland, J.N., Zanos, P., Jacqueline, L., Moaddel, M., Corruble, E., David, D.J.,  Gould, T.D., Denny, C.A., Gardier, A. Ketamine metabolism via hepatic CYP450 isoforms contributes to its sustained antidepressant actions. bioRxiv, 2024.04. 03.587904.
  • Onisiforou, A., Christodoulou, P., Zamba-Papanicolaou, E., Zanos P., Georgiou P. Transcriptomic Analysis Reveals Sex-Specific Patterns in the Hippocampus in Alzheimer’s Disease. Frontiers in Endocrinology, 2024, 15.
  • Bendis, P.C., Zimmerman, S., Onisiforou, A., Zanos P., Georgiou P. The Impact of Estradiol on Serotonin, Glutamate, and Dopamine Systems. Frontiers in Neuroscience, 2024, 18.
  • Onisiforou, A., Michael, A., Georgiou, P., Mammadov, E., Zanos, P. Ketamine metabolites as next-generation pharmacotherapies for treating opioid addiction. Neuropsychopharmacology, 2024, 48 (481-481).
  • Loizou, P., Panayiotou, G., Zanos, P., Paraskevopoulos, E. Exploring the neurofunctional impairments and cognitive biases concerning food and body related stimuli in anorexia nervosa: an integrated EEG and eye-tracking study protocol. Plos One, 2024, 19, e0299529.



  • Michael, A.*, Onisiforou, A.*, Georgiou, P., Koumas, M., Mammadov, E., Zanos, P. (2R,6R)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice. bioRxiv (2023), 12.07.570550. * Equal Contribution.
  • Onisiforou, A., Zanos, P. From Viral Infections to Alzheimer’s Disease: Unveiling the Mechanistic Links Through Systems Bioinformatics. bioRxiv (2023), 12.05.570187.
  • Christodoulou, C.*, Onisiforou, A.*, Zanos, P., Zamba-Papanicolaou, E. Unraveling the transcriptomic signatures of Parkinson’s Disease and Major Depression using single-cell and bulk data. Frontiers Aging Neuroscience (2023) 15. *Equal contribution.
  • Onisiforou, A., Georgiou, P., Zanos, P. Role of group II metabotropic glutamate receptors in the antidepressant actions of ketamine. Pharmacology, Biochemistry and Behaviour, 2023, 223:173531.
  • Zanos, P.*, Brown K.A., Georgiou, P., Yuan, P., Zarate, C.A., Thompson, S., Gould, T.D. NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine. Journal of Neuroscience, 2023, 43, 1038-1050. * Corresponding Author.
  • Brown K.A., Zanos, P., Powels, C.F., Fix, C.J., Michaelides, M., Pereira, E.FR., Moaddel, R., Gould, T.D. Ketamine preservative benzethonium chloride potentiates hippocampal synaptic transmission and binds neurotransmitter receptors and transporters. Neuropharmacology, 2023, 225:109403.



  • Georgiou, P., Zanos, P., Mou, T-C., An, X., Gerhard, D., Dryanovski, I.D., Potter, E.L., Highland, J., Jenne, C., Stewart, B., Pultorak, K., Yuan, P., Powels, C., Lovett, J., Pereira, E., Clark, S., Tonelli, L., Moaddel, R., Zarate, C.A., Duman, R., Thompson, S., Gould, T.D. Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor. Nature Neuroscience, 2022, 25, 1191-1200.
  • Moaddel, R., Zanos, P., Farmer, C.A., Kadriu, B., Morris, P., Lovett, J., Acevedo-Diaz, E., Cavanaugh, G., Yuan, P., Yavi, M., Thomas, C., Park, L.T., Ferrucci, L., Gould, T.D., Zarate Jr, C.A. Comparative Metabolomic Analysis in Plasma and Cerebrospinal Fluid of Humans and in Plasma and Brain of Mice Following Antidepressant-dose Ketamine Administration. Translational Psychiatry2022, 12, 1-9.
  • Bonaventura, J., Gomez, J.L., Carlton, M.L., Lam, S., Sanchez-Soto, M., Morris, P.J., Moaddel, R., Kang, H-J., Zanos, P., Gould, T.D., Thomas, C.J., Sibley, D.R., Zarate Jr, C.A., Michaelides, M. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Molecular Psychiatry, 2022, 27, 4144-4156.
  • Georgiou, P., Zanos, P., Mou, T-C., An, X., Gerhard, D., Dryanovski, I.D., Potter, E.L., Highland, J., Jenne, C., Stewart, B., Pultorak, K., Yuan, P., Powels, C., Lovett, J., Pereira, E., Clark, S., Tonelli, L., Moaddel, R., Zarate, C.A., Duman, R., Thompson, S., Gould, T.D. Experimenter sex modulates mouse biobehavioral and pharmacological responses. BioRxiv.
  • Georgiou, P., Mou, T-C., Potter, L., An, X., Zanos, P., Patton, M., Pultorak, K., Clark, S., Ngyuyen, V., Powels, P., Prokai-Tatrai, K., Merchenthaler, I., Prokai, L., McCarthy, M., Mathur, B., Gould, T.D. Estradiol mediates stress-susceptibility in the male brain. BioRxiv.
  • Highland, J., Morris, P., Konrath, K., Riggs, L., Hagen, N., Zanos, P., Powels, C., Moaddel, R., Thomas, C., Wang, A., Gould, TD. Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)‑Methyl-(2R,6R)‑hydroxynorketamines. ACS Chemical Neuroscience. 2022, 4, 510-523.
  • Troppoli, T., Zanos, P., Georgiou, P., Gould, TD., Rudolph, U., Thompson, S. Negative allosteric modulation of GABAARs at α5 subunit-containing benzodiazepine sites reverses stress-induced anhedonia and weakened synaptic function in mice. Biological Psychiatry, 2022, 92, 216-226.
  • Highland, J., Farmer, C., Zanos, P., Lovett, J., Zarate, CA., Moaddel, R., Gould, TD. Sex-dependent metabolism of ketamine and (2R,6R)-hydroxynorketamine in mice and humans. Journal of Psychopharmacology. 2022, 36, 170-182.



  • Osman, A., Zuffa, S., Walton, G., Fagbodun, E., Zanos, P., Georgiou, P., Kitchen, I., Swann, J., Bailey, A. Post-weaning A1/A2 β-casein milk intake modulates depressive-like behavior, brain μ-opioid receptors and the metabolome of rats. iScience. 2021, 24:103048.
  • Morris, P., Burke, R., Singh, A., Gould, T.D., Zarate, C.A., Zanos, P., Moaddel, R., Thomas, C. A comparison of the pharmacology and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine, and MK-801. Neurotoxicology and Teratology. 2021, 87:106993.
  • Highland, J.N., Zanos, P., Riggs, M.L., Georgiou, P., Clark, S.M., Morris, P.J., Moaddel, R., Thomas, C., Zarate, C.Jr., Pereira, E.F.R., Gould, T.D., Hydroxynorketamines: Pharmacology and potential therapeutic applications. Pharmacological Reviews, 2021, 63, 763-791.



  • Elmer, G., Tapocik, J., Mayo, C., Zanos, P., Gould, T.D. Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma. Pharmacology, Biochemistry and Behavior, 2020, 196:172973.
  • Park, L.T., Kadriu, B., Gould, T.D., Zanos, P., Grreenstein, D., Evans, J.W., Yuan, P., Farmer, C.A., Oppenheimer, M., George J.M., Adeojo, L.W., Snodgrass, H.R., Smith, M.A., Henter, I.D., Machado-Vieira, R., Mannes, A.J., Zarate, C.A. A randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. International Journal of Neuropsychopharmacology2020, 23, 417-425.
  • Zhang, Y., Zanos,P., Jackson, I., Zhang, X., Zhu, X., Gould, T.D., Vujaskovic, Z. Psychological stress enhances tumor growth and diminishes radiation response in preclinical model of lung cancer. Radiotherapy and Oncology, 2020, 146, 126-135.
  • Krimmel, S.R.*, Zanos, P.*, Georgiou, P., Colloca, L., Gould, T.D. Classical conditioning of antidepressant placebo effects in mice. Psychopharmacology2020, 237, 93-102. * Equal contribution.
  • Riggs, L., Aracava, Y., Zanos, P., Fischell, J., Albuquerque, E.X., Perreira, E.F.R., Thompson, S.M., Gould, T.D. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacology2020, 45, 426-436.



  • Highland, J.N., Zanos, P., Georgiou, P., Gould, T.D. Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. Neuropsychopharmacology2019, 44, 1788-1796.
  • Zanos, P., Highland, J.N., Georgiou, P., Jenne, C.E., Morris, P.J., Moaddel, R., Xye, J.K., Zarate Jr, C., Gould, T.D. (2R,6R)-hydroxynorketamine exerts mGlureceptor-dependent antidepressant actions. PNAS, 2019, 116, 6441-6450.
  • Zanos, P., Highland, J.N., Xin, L., Georgiou, P., Stewart, B.W., Moaddel, R., Xye, J.K., Gould, T.D. (R)-ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anesthetic doses. British Journal of Pharmacology, 2019, 176 2573-2592.
  • Rao, X., AsicoL.D., Zanos,P., Mahabeleshwar, G.H., Gangwar, R.S.,Xia, C., Duan,L., Cisse,YM., Rengasamy, P., Jose,P.A., Gould, T.D., Nelson,R., Biswal,S., Chen,LC., Zhong,J., Rajagopalan,S. Alpha2B-adrenergic receptor overexpression in the brain potentiates air pollution-induced behavior and blood pressure changes. Toxicological sciences2019, 169, 95-107.
  • Georgiou, P., Zanos, P., Jenne, E.C., Gould, T.D. Sex-specific involvement of estrogen receptors in behavioral responses to stress and psychomotor activation. Frontiers in Psychiatry2019; 10:81.
  • Lumsden, E. *, Troppoli, T.A. *, Myers, S.J., Zanos, P., Aracava, Y., Kehr, J., Moaddel, R., Kim, S., Wang, F-H., Schmidt, S., Jenne, C.E., Yuan, P., Morris, P.J., Zarate, Jr, C.A., Thomas, C. J., Traynelis, S.F., Pereira, E. F.R., Thompson, S.M., Albuquerque, E.X., Gould, T.D. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. PNAS2019, 116,5160-5169.



  • Zanos, P., Keyworth, H., Georgiou, P., Kitchen, I., Zimmer, A., Bailey, A. Chronic nicotine administration restores brain region specific upregulation of oxytocin receptor binding levels in a G72 mouse model of schizophrenia. European Journal of Neuroscience, 2018, 50, 2255-2263.
  • Rae, M., Zanos, P., Georgiou, P., Chivers, P., Bailey, A., Camarini, R. Environmental enrichment enhances conditioned place preference to ethanol via an oxytocinergic-dependent mechanism in male mice. Neuropharmacology2018, 138, 267-274.
  • Zanos, P., Moaddel, R., Morris, P.J., Riggs, L.M., Highland, J.N., Georgiou, P., Pereira, E.F.R., Albuquerque, E.X., Thomas, C., Zarate Jr, C., Gould, T.D. Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews2018, 70, 621-660.
  • Zanos, P.*, Gould, T.D. Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 2018, 23, 811-817. Corresponding author
  • Zanos, P.*, Duman, R.S., Thompson, S.M., Zarate Jr, C., Gould, T.D. Convergent mechanisms underlying rapid antidepressant action. CNS Drugs2018, 32, 197-227. * Corresponding author.
  • Brown, P.L.*, Zanos, P.*, Wang, L., Mayo C.L., Elmer, G.I., Gould, T.D., Shepard, P.C. Isoflurane but not halothane prevents and reverses helpless behavior: a role for burst suppression? International Journal of Neuropsychopharmacology2018, 21, 777-785. *Equal contribution.



  • Garcia-Carmona, J.A., Georgiou, P., Zanos, P., Bailey, A., Laorden, M.L. Methamphetamine withdrawal induces activation of CRF neurons in the brain stress system in parallel with an increased activity of cardiac sympathetic pathways. Naunym-Schmiedeberg Archives Pharmacology2017, 391, 1-12.
  • Keyworth, H., Georgiou, P., Zanos, P.Veloso Rueda A., Chen Y., Kitchen I., Camarini R., Cropley M., Alexis Bailey A. Wheel running during chronic nicotine exposure is protective against mecamylamine-precipitated withdrawal and up-regulates hippocampal α7 nACh receptors in mice. British Journal of Pharmacology2017, 175, 1928-1943.
  • Morris, P.J., Moaddel R., Zanos, P., Moore C.E., Gould T.D., Zarate C.A. Jr, Thomas, C.J. Synthesis and NMDA receptor activity of ketamine metabolites. Organic letters, 2017, 19, 4572-4575.
  • Georgiou, P., Zanos, P., Bhat S., McCarthy, P., Merchenthaler, I., Tracy, J.K., Gould, T.D. Dopamine and stress system modulation of sex differences in decision-making. Neuropsychopharmacology, 2017, 43, 313-324.
  • Zanos, P., Moaddel, R., Morris, P., Georgiou, P., Fischell, J., Elmer, G., Alkondon, M., Yuan, P., Pribut, H., Singh, N., Dossou, K., Fang, Y., Huang, XP., Mayo, C., Albuquerque, E., Thompson, S., Thomas, C., Zarate Jr, C., Gould, T.D. BCA: Effects of a ketamine metabolite on synaptic NMDAR function. Nature, 2017, 546, E4-E5.
  • Zanos, P., Nelson, M.E, Krimmel, S.R., Highland, J.N., Georgiou, P., Gould, T.D., Thompson, S.M. A negative allosteric modulator for alpha5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant action without the side effects of the NMDA receptor antagonist ketamine in mice. eNeuro, 2017, 4, pii: ENEURO.0285-16.2017.
  • Zanos, P., Georgiou, P., Weber, C., Robinson, F., Kouimtsidis, C., Niforooshan, R., Bailey, A. Oxytocin and opioid addiction revisited: Old drug, new applications. British Journal of Pharmacology, 2017, 175, 2809-2824.
  • Martynhak, B., Hogben, A., Zanos, P., Georgiou, P., Andreatini, R., Kitchen, I., Archer, S., von Schantz, M., Bailey, A., van der Veen, D. Transient anhedonia phenotype and altered circadian timing of behaviour during night-time dim light exposure in Per3−/− mice, but not wildtype mice. Scientific Reports, 2017, 7:40399.
  • Gould, T.D., Georgiou, P., Brenner, L.A., Brundin, L., Can, A., Courtet, P., Donaldson, Z.R., Dwivedi, Y., Guillaume, S., Gottesman, I.I., Kanekar, S., Lowry, C.A., Renshaw, P.F., Rujescu, D., Smith, E.G., Turecki, G., Zanos, P., Zarate Jr, C., Zunszain, P.A., Postolache, T.T. Animal models to improve our understanding and treatment of suicidal behavior. Translational Psychiatry, 2017, 7, 1-22.



  • Gould, T.D., Zanos, P., Zarate Jr, C. Ketamine mechanism of action: separating the wheat from the chaff. Neuropsychopharmacology, 2016, 42, 368-369.
  • Zanos, P., Moaddel, R., Morris, P., Albuquerque, E., Wainer, I., Thompson, S., Thomas, C., Zarate Jr, C., Gould, T.D. Antidepressant actions of ketamine versus Hydroxynorketamine. Biological Psychiatry, 2016, 81, 69-71.
  • Can, A.*, Zanos, P.*, Moaddel, R., Huang, XP., Kang, H.J., Dossou, SS.D., Wainer, I.W., Cheer, J.F., Frost, D.O., Roth, BL., Gould, T.D. Effects of ketamine on electrically-evoked accumbal dopamine release and activity at dopamine receptors and transporters. JPET2016, 359, 159-170. *Equal contribution.
  • Georgiou, P., Zanos, P., Hourani, S., Kitchen, I., Bailey, A. Cocaine abstinence induces emotional impairment and brain region-specific upregulation of the oxytocin receptor binding. European Journal of Neuroscience, 2016, 4424462454.
  • Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G., Alkondon, M., Yuan, P., Pribut, H., Singh, N., Dossou, K., Fang, Y., Huang, XP., Mayo, C., Wainer, I., Albuquerque, E., Thompson, S.M., Thomas, C., Zarate Jr, C., Gould, T.D. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature2016, 533, 481-486.
  • Georgiou, P., Zanos, P., Garcia-Carmona, J.A., Hourani, S., Kitchen, I., Laorden, M.L., Bailey, A. Methamphetamine withdrawal induces an anxiogenic-like phenotype and brain region-specific alterations of the oxytocin and mu-opioid receptors in mice. Neuropharmacology, 2016, 105, 520-532.



  • Zanos, P., Piantadosi, S., Wu, HQ., Pribut, H., Dell, M., Can, A., Snodgrass, H.R., Zarate, C., Schwarcz, R., Gould, T. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. JPET2015, 355, 76-85.
  • Wright, R.S.*, Zanos, P.*, Yoo, J.H., Winsky-Sommerer, R., Hourani, S., Kitchen, I., Bailey, A. A critical role of striatal A2AR-mGlu5R interactions in modulating the psychomotor and drug-seeking effects of methamphetamine. Addiction Biology, 2015, 4, 811-825. *Equal contribution.
  • Georgiou, P., Zanos, P., Hourani, S., Kitchen, I., Bailey, A. The oxytocin analogue carbetocin prevents priming-induced reinstatement of morphine-seeking: involvement of the dopaminergic, noradrenergic and MOPr systems. European Journal of Neuropsychopharmacology, 2015, 12, 2459-2464.
  • Zanos, P., Bhat, S., Smith, R., Terrillion, C., Tonelli, L., Gould, T.D. Sex-dependent modulation of sex-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav2). European Journal of Neuroscience 2015, 42, 2499-507
  • Zanos, P., Georgiou, P., Metaxas, A., Kitchen, I., Winsky-Sommerer, R., Bailey, A. Region-specific up-regulation of oxytocin receptor binding in the brain of mice following chronic nicotine administration. Neuroscience Letters, 2015, 60033-37.
  • Georgiou, P., Zanos, P., Ehteramyan, M., Hourani, S., Kitchen, I., Maldonado, R., Bailey, A. Differential regulation of mGlu5R and MOPr by priming- and cue-induced reinstatement of cocaine-seeking in mice. Addiction Biology, 2015, 20, 902-12.
  • Zanos, P., Georgiou, P., Hourani, S., Kitchen, I., Winsky-Sommerer, R., Bailey, A. Emotional impairement and persistent up-regulation of mGlu5 receptor following morphine abstinence: implications an mGlu5-MOPr interaction. International Journal of Neuropsychopharmacology, 2015, 19, 1-10.



  • Chao, M., Fragou, D., Zanos, P., Hu, C., Bailey, A., Kouidou, S., Kovatsi, L. Epigenetically modified nucleotides in chronic heroin and cocaine treated mice. Toxicology letters, 2014, 229, 451-7.
  • Zanos, P., Wright, R.S., Georgiou, P., Yoo, J.H., Hourani, S., Ledent, C., Winsky-Sommerer, R., Kitchen, I., Bailey, A. Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A2A receptor-independent mechanism. Pharmacology, Biochemistry and Behavior, 2014, 119, 72-9
  • Zanos, P., Georgiou, P., Wright, R.S., Kitchen, I., Winsky-Sommerer, R., Bailey, A. The oxytocin analogue carbetocin attenuates emotional impairment and blocks stress-induced reinstatement of morphine-seeking in morphine abstinent mice. Neuropsychopharmacology, 2014, 39, 855-865.



  • Fragou, D., Zanos, P., Kouidou, S., Njau, S., Kitchen, I., Bailey, A., Kovatsi, L. Effect of chronic heroin and cocaine administration on global DNA methylation in brain and liver. Toxicology letters, 2013, 218, 260-5.